RCT | Ide-cel (a CAR-T cell treatment) vs. standard regimens in relapsed and refractory multiple myeloma
13 Feb, 2023 | 12:41h | UTCIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma – HealthDay
Ide-cel Improves PFS vs SOC in Relapsed/Refractory Multiple Myeloma – OncLive